B7-06: Mass Spectrometry Profiling of Low Molecular Weight Platelet Proteome for the Detection of Lung Cancer Specific Biomarkers  by De Petris, Luigi et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS356
The presence of EGFR mutations was also determined in archival 
tumor material and/or plasma obtained from 39 consenting advanced 
stage NSCLC patients treated with EGFR-TKIs. 
Results: In cell line experiments, mutant DNA was detectable utilizing 
the Scorpion technology at concentrations as low as 25 pg, and at ratios 
as little as 0.1% of the total pool of genomic DNA. Of the 39 NSCLC 
patients, only tissue was available for evaluation in seven patients; two 
were positive both with the Scorpion primers and direct sequencing 
while the rest were wild-type. For 21 patients where only plasma was 
available, 6 mutations were detected with Scorpion primers, none of 
which were detectable by direct sequencing. EGFR mutations were 
identiﬁed in both plasma and tissue of two patients who were complete 
responders to EGFR-TKI therapy, only one of which was detectable by 
direct sequencing. Two additional mutations were found in the tissue 
but not plasma of patients currently undergoing treatment. Neither of 
these mutations was detectable by direct sequencing.
Conclusions: Allele-speciﬁc Scorpion technology is: 1) highly speciﬁc 
and sensitive for EGFR mutation analysis, 2) able to detect mutations 
not observable by direct sequencing in plasma and tissue, 3) capable 
of detecting mutations in shed tumor DNA in plasma and 4) may be 
suitable for monitoring response or detecting recurrence in advanced 
NSCLC patients. 
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Background: The presence of somatic mutations in epidermal growth 
factor receptor (EGFR) predicts the response of EGFR tyrosine kinase 
inhibitors (TKIs). It has been reported that exon 19 and 21 mutation 
correlates with the effectiveness and exon 20 mutation correlates with 
the resistance of EGFR-TKIs. It would be ideal if EGFR mutation 
can be detected by biopsy samples, since the majority of non-small 
cell lung cancer patients at the time of presentation are inoperable. 
We have reported the usefulness of endobronchial ultrasound guided 
transbronchial needle aspiration (EBUS-TBNA). EBUS-TBNA has a 
high sensitivity as well as speciﬁcity for mediastinal and hilar lymph 
node staging in patients with lung cancer. EBUS-TBNA is a real-time 
procedure that enables multiple biopsies with good histological cores. 
Methods: The purpose of this study was to develop and analyze 
the feasibility of detecting EGFR mutation in samples obtained by 
EBUS-TBNA. Fifty six patients with primary lung cancer diagnosed 
as metastatic adenocarcinoma in hilar and/or mediastinal lymph node 
by EBUS-TBNA were analyzed. We extracted DNA from parafﬁn 
embedded samples and investigated the EGFR mutation in exon 19 and 
21 using a newly developed Loop- Hybrid Mobility Shift Assay (LH-
MSA). The results were conﬁrmed by direct sequence method in the 
ﬁrst 46 cases. Furthermore we analyzed the exon 19 to 21 in 10 cases 
using LH-MSA.
Results: Out of the 56 cases, 53 cases contained tumor cells in re-
sliced parafﬁn embedded specimens and were analyzed. Thirty four 
patients (64.2%) were male. EGFR mutation was detected in 15 cases 
(30.2%); three cases were in-ﬂame deletion of exon 19, one case was 
point mutation of exon 20, and 12 cases were point mutation of exon 
21. 52.6% of the female population (10 out of 19 cases) showed EGFR 
mutation. Two cases with exon 21 point mutation were treated by ge-
ﬁtinib. A case with multiple mediastinal lymph node metastases along 
with malignant pericardial effusion showed a signiﬁcant decrease in 
size of the tumor two weeks after the administration of geﬁtinib and has 
been alive for 22 months.
Conclusions: EGFR mutation can easily be detected in metastatic 
lymph nodes sampled by EBUS-TBNA. EBUS-TBNA allows genetic 
evaluations of tumor cells within the lymph node and may provide 
us with indications for EGFR-TKI therapy before administration of 
EGFR-TKIs therapy in the near future. EBUS-TBNA samples will 
possibly provide other molecular biological information which will be 
useful for the treatment of advanced and recurrent lung cancer disease
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Background: In preclinical models, proteomic proﬁling has revealed 
that circulating platelets selectively take up tumor-derived angiogenesis 
regulatory proteins (J. Folkman et al. FASEB J 20:A414,2006). The 
aim of this study was to assess whether this novel function of platelets 
could be efﬁciently explored with proteomic proﬁling of the low mo-
lecular weight (LMW) proteome, and further reveal lung cancer (LC) 
speciﬁc markers. 
Methods: Blood samples (4-ml EDTA tubes) were collected from 
54 patients (29 with newly diagnosed advanced NSCLC and 25 with 
benign lung diseases) under the same conditions. Written informed 
consent was obtained from all patients. LC patients included 18 
adenocarcinomas, 7 squamous tumors, 2 large cell carcinomas and 2 
low differentiated NSCLC. The control group included 5 patients with 
hamartoma, 14 with non-speciﬁc lung inﬁltrate and 6 with diverse be-
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nign conditions. The two patient groups were matched with respect to 
gender, age, smoking habits, number and class of current medications. 
Patients with benign diseases had a higher median number of co-mor-
bidities compared to LC patients (2 vs 1; p<0.01). As expected, mean 
platelet concentration in the blood samples was higher in the LC group 
compared with the control group (370,000/μl vs 292,000/μl, p=0.01). 
Within 2 hours after blood sample collection, platelets were isolated 
from plasma using a separation protocol based on sequential centrifu-
gations. Protein concentration was normalized to 2 g/l. Platelet lysates 
were proﬁled in duplicates on a strong anionic exchange (Q10, pH 7.5) 
ProteinChip array, using SELDI-TOF-MS technology. Analyzed mass 
range was 2,600-20,000 Da. Peaks were detected and quantiﬁed using 
our newly developed method based on ‘regions of signiﬁcance’ (C.S. 
Tan et al. Proteomics 6:6124,2006). Differences in median relative 
peak intensity between groups were assessed using the Mann-Whitney 
non parametric test. Signiﬁcantly different peaks at this univariate 
analysis were considered potential biomarkers. Multivariate analysis 
was performed using the supervised partial least square discriminant 
analysis (PLS-DA). 
Results: Spectra showed a very high homology (mean peak intensity 
CV=46%) despite the expected inter-individual variability, indicating 
the good reproducibility of the sample preparation method. Overall, ap-
proximately 200 peaks were detected. 7 unique peaks were signiﬁcantly 
more expressed in LC group compared to the control group (p<0.05). 
Differences in protein expression due to drugs affecting platelet func-
tion, such as low dose acetylsalicylic acid, and drugs taken by at least 
20% of patients, were also investigated. 5 and 37 unique peaks were 
signiﬁcantly related to the administration of acetylsalicylic acid and 
inhalation adrenergics, respectively. Furthermore, the PLS-DA pro-
vided an initial assessment of the most important discriminant variables 
that in combination were able to separate LC patients from the control 
group, although the prediction properties of this model are still to be 
elucidated. 
Conclusions: The preliminary data from this pilot study conﬁrm the 
hypothesis that the platelet LMW proteome can be a source of biomark-
ers of systemic diseases, such as advanced LC, that are not directly 
related to platelet function. 
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Introduction: Deletions in the 10q region are a relatively common and 
early ﬁnding in NSCLC. FISH is a reproducible and accurate technique 
of detecting these deletions in clinical specimens. This study looks at 
10q deletions detected by FISH in different regions of the airway in pa-
tients undergoing surgical resection of NSCLC in an effort to determine 
the feasibility of using FISH for early diagnosis of lung cancer.
Methods: FISH was performed on specimens from 120 patients with 
probes developed in house on specimens from ﬁve different areas: 
1 NBB:Brush biopsy from bronchoscopically normal mainstem bron-
chus from the side opposite the tumor
2 TBB:Brush biopsy from bronchoscopically normal mainstem bron-
chus from the side of the tumor
3 TAB:Touch preparation from normal bronchus adjacent to the tumor
4 TTP:Touch preparation from the tumor
5 NTP:Touch preparation from normal lung away from the tumor
A FISH assay using probes complementary to 10q22.3 and the centro-
mere of chromosome 10 were used. 10q was considered to be deleted if 
there were fewer 10q signals when compared to centromeric 10 signals. 
The Wilcoxon signed rank test was used to compare the ratio of the 
percentage of deletions detected at different anatomic sites. Correla-
tions of deletions at different sites were estimated using a Spearman 
correlation coefﬁcient.
Results: Contralateral normal bronchial tissue (NBB) showed a 
relatively low deletion rate at 10q compared to tumor tissue (TTP) 
(p<0.0001). FISH on brush biopsies at TBB showed a signiﬁcantly 
higher rate of deletions compared to NBB but lower than TTP from the 
tumor (p<0.05). A signiﬁcantly higher deletion rate was seen at TTP 
compared to NTP at the 10 q regions (p<0.0001) (Figure 1). Signiﬁcant 
correlations were seen between the rate of deletions between TTP and 
TAB at 10q (σ=0.64, p<0.0001).
Conclusion: 10q chromosomal deletions can be reliably detected by 
FISH in bronchoscopic brush biopsies and tumor touch preparations. 
As one progresses from area of the lung and bronchus away from the 
tumor to areas proximate to the tumor, the 10q deletion rate increases in 
a statistically signiﬁcant fashion, supporting an etiologic role of these 
deletions. 10q deletions in bronchoscopically normal areas correlate 
with increased deletion rate in the tumor itself, suggesting that this test 
may be useful in early diagnosis of NSCLC.
